|
Gene: ZNF470 |
Gene summary for ZNF470 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF470 | Gene ID | 388566 |
Gene name | zinc finger protein 470 | |
Gene Alias | CZF-1 | |
Cytomap | 19q13.43 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6ECI4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
388566 | ZNF470 | HCC1 | Human | Liver | HCC | 8.27e-05 | 1.38e+00 | 0.5336 |
388566 | ZNF470 | HCC2 | Human | Liver | HCC | 3.94e-24 | 3.89e+00 | 0.5341 |
388566 | ZNF470 | HCC5 | Human | Liver | HCC | 7.23e-03 | 1.85e-01 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF470 | SNV | Missense_Mutation | c.159N>T | p.Leu53Phe | p.L53F | Q6ECI4 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
ZNF470 | SNV | Missense_Mutation | novel | c.1445N>G | p.Glu482Gly | p.E482G | Q6ECI4 | protein_coding | deleterious(0.02) | benign(0.005) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF470 | SNV | Missense_Mutation | c.1438N>T | p.Pro480Ser | p.P480S | Q6ECI4 | protein_coding | deleterious(0) | possibly_damaging(0.72) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ZNF470 | SNV | Missense_Mutation | c.1444N>C | p.Glu482Gln | p.E482Q | Q6ECI4 | protein_coding | deleterious(0.04) | benign(0.239) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF470 | SNV | Missense_Mutation | c.879C>A | p.Phe293Leu | p.F293L | Q6ECI4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
ZNF470 | SNV | Missense_Mutation | c.1147C>G | p.Leu383Val | p.L383V | Q6ECI4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
ZNF470 | SNV | Missense_Mutation | novel | c.1358N>T | p.Tyr453Phe | p.Y453F | Q6ECI4 | protein_coding | tolerated(0.11) | benign(0.151) | TCGA-PL-A8LX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ZNF470 | insertion | Frame_Shift_Ins | novel | c.1444_1445insT | p.Glu482ValfsTer3 | p.E482Vfs*3 | Q6ECI4 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ZNF470 | SNV | Missense_Mutation | c.733N>T | p.Leu245Phe | p.L245F | Q6ECI4 | protein_coding | tolerated(0.09) | probably_damaging(0.995) | TCGA-C5-A1BN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
ZNF470 | SNV | Missense_Mutation | novel | c.136A>C | p.Ser46Arg | p.S46R | Q6ECI4 | protein_coding | tolerated(0.18) | benign(0.059) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |